Author:
Kabootari Maryam,Shirmohammadli Habibeh,Golgiri Fatemeh,Mosalamiaghili Seyedarad,Khajavi Alireza,Akbari Hamideh
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference37 articles.
1. M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao. Advances in the treatment of prolactinomas. 27(5), 485–534 (2006)
2. B.A. Doğan, A. Arduç, M.M. Tuna, N.I. Nasıroğlu, S. Işık, D. Berker et al. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatol. J. Cardiol. 16(6), 440 (2016)
3. R. Haring, N. Friedrich, H. Völzke, R.S. Vasan, S.B. Felix, M. Dörr et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur. Heart J. 35(18), 1215–1221 (2014)
4. A. Jurek, P. Krzesiński, G. Gielerak, B. Uziębło-Życzkowska, P. Witek, G. Zieliński et al. Prolactinoma and cardiovascular diseases–an interdisciplinary problem. Pediatr. Med Rodz. 2021 17(4), 294–298 (2021). https://doi.org/10.15557/PiMR.2021.0046
5. O. Serri, L. Li, J.C. Mamputu, M.C. Beauchamp, F. Maingrette, G. Renier, The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. 64(4), 366–370 (2006)
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献